Novo Nordisk has presented a strategic plan to rejuvenate growth as it faces the impending patent expirations of its leading drugs, Wegovy and Ozempic, around the early 2030s. At a recent Capital Markets Day, the Danish company unveiled a pipeline of potential blockbuster medications aimed at diversifying from its core focus on obesity and diabetes. However, investor enthusiasm has waned, as Wall Street reacted negatively to growth targets that fell in line with industry averages and uncertainty regarding a near-term recovery plan.
In contrast, Eli Lilly is steadily increasing its market share, including within the newly emerging oral obesity treatment space. Lilly’s new obesity pill, Foundayo, is gaining traction in the U.S., with CEO Dave Ricks reporting that one-third of newly prescribed GLP-1 pill patients are opting for Foundayo. The company’s significant foothold in the Medicare market also contributes to its dominance, claimed to hold a 61% share in the U.S. GLP-1 market as of Q2.
Despite some challenges, analysts predict Lilly will maintain its leadership position, citing its robust commercial resources and advanced pipeline of upcoming drugs such as retatrutide, expected to enter approval processes in 2027. Novo’s CEO Mike Doustdar remains optimistic about the potential growth of oral obesity treatments, targeting a manufacturing capacity that could support 15 million patients by 2030.
Ultimately, Novo faces a dual challenge: safeguarding its current market leadership while simultaneously developing future drugs to replace its core revenue sources.
Why this story matters: The competitive landscape of obesity treatments influences market dynamics and patient access to medications.
Key takeaway: Eli Lilly is gaining momentum against Novo Nordisk, leveraging new product launches and a strong market share.
Opposing viewpoint: Investors remain cautious about Novo’s growth strategy and pipeline prospects in light of upcoming patent expirations.
